Enanta Pharmaceuticals Inc (ENTA)

[floblu14]

Patent Assigned to Enanta Pharmaceuticals, Inc.

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
Type: Grant
Filed: May 19, 2021
Date of Patent: April 16, 2024

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

In certain embodiments, the FXR-mediated disease or condition is cardiovascular disease, atherosclerosis, arteriosclerosis, hypercholesteremia, or hyperlipidemia chronic liver disease, gastrointestinal disease, renal disease, metabolic disease, cancer (i.e., colorectal cancer), or neurological indications such as stroke.

https://patents.justia.com/patent/11958879